CN-AML patients are considered to be an intermediate-risk prognosis category, and prognosis can be further divided into subgroups based on favorable (NPM1, CEBPA) or unfavorable (FLT3-ITD) genetic mutations. This evidence concerns the gene CEBPA and acute myeloid leukemia.